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Abstract
Glyoxalase 1 (Glo1) is a cytoplasmic enzyme with a cytoprotective function linked to
metabolism of the cytotoxic side-product of glycolysis, methylglyoxal. It prevents dicarbonyl
stress – the abnormal accumulation of reactive dicarbonyl metabolites increasing protein and
DNA damage. Increased Glo1 expression delays ageing and suppresses carcinogenesis,
insulin resistance, cardiovascular disease and vascular complications of diabetes and renal
failure. Surprisingly gene trapping by the International Mouse Knockout Consortium (IMKC)
to generate putative Glo1 knockout mice produced a mouse line with phenotype characterised
as normal and healthy. Here we show that gene trapping mutation was successful but the
presence of Glo1 gene duplication, likely in the embryonic stem cells before gene trapping,
maintained wild-type levels of Glo1 expression and activity and sustained the healthy
phenotype. In further investigation of the consequences of dicarbonyl stress in embryonic
stem cells (ESCs), we found prolonged exposure of mouse ESCs in culture to high
concentrations of methylglyoxal and/or hypoxia led to low level increase in Glo1 copy
number. In clinical translation, we found increased prevalence of low level GLO1 copy
number increase in renal failure where there is severe dicarbonyl stress. In conclusion, the
IMKC Glo1 mutant mouse is not deficient in Glo1 expression through duplication of the
Glo1 wild-type allele. Dicarbonyl stress and/or hypoxia induces low level copy number
alternation in embryonic stem cells. Similar processes may drive rare GLO1 duplication in
health and disease.
Summary statement
Unrecognised Glo1 gene duplication led to failure of IMKC project production of a Glo1
deficient mouse. Dicarbonyl stress and/or hypoxia induced low level Glo1 copy number
increase in mouse embryonic stem cells. Copy number alternation may drive clinical GLO1
copy number increase.
Running title: Copy number alteration of glyoxalase 1.
Keywords: glyoxalase; copy number variation; methylglyoxal; embryonic stem cell;
dicarbonyl stress; hypoxia.
2Abbreviations: AF, attachment factor; Btbd9, BTB (POZ) Domain Containing 9; CAT,
catalase; CGH, comparative genomic hybridization; CNV, copy number variation; Dnahc8,
dynein, axonemal, heavy chain 8; EDTA, ethylenediaminetetra-acetic acid; EMMA,
European Mutant Mouse Archive; ESC, embryonic stem cell; Glo1, Glo1 and GLO1, protein,
murine gene and human gene of glyoxalase 1, respectively; Glo2, glyoxalase 2; Glp1r,
glucagon-like peptide 1 receptor; GSH, reduced glutathione; HIF1α, hypoxia-inducible factor 
1-alpha; IMKC, International Mouse Knockout Consortium; KDM4A, lysine-specific
demethylase 4A; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MDR,
multidrug resistance; MEF, mouse embryonic fibroblast; mESC, mouse embryonic stem cell;
MG, methylglyoxal; MGdG, 3-(2’-deoxyribosyl)-6,7-dihydro-6,7-dihydroxy-6/7-
methylimidazo-[2,3-b]purine-9(8)one; MG-H1, N-(5-hydro-5-methyl-4-imidazolon-2-yl)-
ornithine; Nrf2, Nuclear factor erythroid 2–related factor 2; Oct4, octamer-binding
transcription factor 4; PCR, polymerase chain reaction; PRT, paralogue ratio test; PLS-DA,
partial least squares-discriminant analysis; RT-PCR, reverse transcription- polymerase chain
reaction; SDS-PAGE, sodium dodecylsulfate-polyacrylamide gel electrophoresis; SNP,
single nucleotide polymorphism; SOX2, sex determining region Y-box 2; TERT, Telomerase
reverse transcriptase; Tfrc, transferrin receptor; Vmn2r111 and Vmn2r112, vomeronasal 2,
receptors 111 and 112 respectively.
INTRODUCTION
Glyoxalase 1 (Glo1) is part of the glyoxalase metabolic pathway in all mammalian cells and
tissues [1] (Figure 1a). The glyoxalase pathway consists of two enzymes, Glo1 and
glyoxalase 2 (Glo2), and a catalytic amount of reduced glutathione (GSH). The major
function of the pathway is detoxification of methylglyoxal (MG). Glo1 catalyses the
conversion of the hemithioacetal formed non-enzymatically from MG and GSH to S-D-
lactoylglutathione; and Glo2 catalyses the hydrolysis of S-D-lactoylglutathione to D-lactate,
reforming GSH consumed in the Glo1-catalysed step. MG is formed mainly by the non-
enzymatic degradation of triosephosphate intermediates of glucose metabolism – which is an
unavoidable minor “leak” of ca. 0.1% glucose flux from anaerobic glycolysis [2, 3]. MG is a
highly potent glycating agent and, although formed at relatively low flux, its high reactivity
leads to formation of some of the most quantitatively important endogenous damaging
modifications of protein and DNA: arginine-derived hydroimidazolone MG-H1 and
deoxyguanosine-derived imidazopurinone MGdG [4, 5] (Figure 1b and 1c). Glo1 suppresses
the steady-state level of MG and thereby also suppresses the level of MG-H1 and MGdG to
low tolerable levels; 1 – 2% of protein and 1 in 105 nucleotides, respectively [4, 5].
Suppression of DNA modification by MG and related mutation likely underlies the finding
that Glo1 is a tumour suppressor gene [6]. Increased MG-H1 and related protein inactivation
and dysfunction contributes to ageing [7], insulin resistance [8, 9], cardiovascular disease
[10], vascular complications of diabetes [4, 11] and renal failure [12]. Increased MG
concentration, a metabolic state called dicarbonyl stress, is driven by increased formation of
MG and/or decreased activity of Glo1 [1]. To counter periods of increased MG formation,
expression of Glo1 is under stress-responsive transcriptional control through transcription
factor Nrf2 which binds to a functional regulatory antioxidant response element and increases
Glo1 expression [13].
To investigate the role of Glo1 activity in maintenance of health and prevention of
disease we acquired putative Glo1 knockout mice produced by the International Mouse
Knockout Consortium (IMKC) [14]. Murine Glo1 is located at 17a3.3 (30592866–30612659)
and has 6 exons. Glo1 is diallelic with each allele coding for a 21.5 kDa subunit of Glo1
dimer protein, running at 23 kDa in SDS-PAGE [15]. A rare polymorphism produces
genotypes Glo1a (common) and Glo1b (rare) which, like human GLO1, gives rise to
3allozymes of similar molecular mass and enzymatic activity [16, 17]. The IMKC Glo1
mutant mouse was produced by gene trapping, with retroviral insertion of vector VICTR48
between exons-1 and -2 in strain 129SvEvBrd-derived mESCs and bred in a C57BL/6J
background. From the phenotypic characterisation data provided by the supplier - Lexicon
Pharmaceuticals (Woodlands, Texas, USA) and included in the European Mutant Mouse
Archive (EMMA) described of the Glo1 mutant mouse, it was surprising to find report of a
normal, healthy phenotype in both putative homozygous and heterozygous Glo1 mutant mice.
Rare mutation of GLO1 in the human population is embryonically lethal in homozygous
inheritance with increased risk of severe neurological disorders in heterozygous inheritance [18].
Glo1 knockout mice have otherwise been elusive and rather a mouse strain with Glo1 deficiency
was developed by viral insertion of a vector expressing Glo1 siRNA [19]. Silencing and
chemical inhibition of Glo1 in mice was linked to increased vascular disease [20-22]. If Glo1
expression had been decreased by 50% in heterozygote Glo1 mutant mice by successful gene
trapping - as expected for functional knockout, a ca. 2-fold increased MG and consequent
impaired metabolic, vascular and neurological health in the mutant mouse model is expected
[8, 20-22]. In the IMKC project, the putative mutation of the Glo1 gene was assessed by
measurement of Glo1 mRNA only.
The aim of this study was to assess if the Lexicon Glo1 mutant mice were protected
against dicarbonyl stress through an alternative fate of MG metabolism, or other mechanism.
We therefore developed genotyping methodology for detection of the Glo1 mutation and
evidence of putative disruption of Glo1 expression. We also characterised the glyoxalase system
of mouse embryonic stem cells (mESCs) in vitro and modelled dicarbonyl stress by exposure to
exogenous MG. Clinical translation of the findings was assessed in patients with renal failure
– an example of severe dicarbonyl stress.
Herein we present conclusive evidence that mutant mice created by gene trapping of
Glo1 in the IMKC project are not deficient in Glo1 expression and activity, which explains
why the healthy phenotype was preserved. We confirm that Glo1 was mutated and reveal the
compensatory mechanism for Glo1 expression – wild-type Glo1 gene duplication, which was
likely present in the mESC line before gene trapping. Additionally we show that experimental
dicarbonyl stress and hypoxia induce low level Glo1 copy number increase in mESCs in vitro
and in clinical translation we found increased prevalence of low level GLO1 copy number
increase in renal failure, suggesting dicarbonyl stress and/or hypoxia-induced copy number
alteration of GLO1 may occur physiologically.
EXPERIMENTAL
Glo1 mutant and wild type mice
Glo1 mutant mice produced by Lexicon Pharmaceuticals (the Woodlands, Texas, USA) were
obtained as a heterozygote breeding pair from EMMA, Heidelberg, Germany. Wild-type
control siblings of heterozygote C57BL/6 mice were produced in the Biological Services
Unit, University of Warwick. Animal breeding was performed under Licence number
80/2556 (Breeding and maintenance of genetically altered rodents) approved by the Home
Office U.K. and conducted in accordance with the requirements of the UK Animals
(Scientific Procedures) Act 1986. Control mouse liver samples of strains C57BL/6J (stock
number: 664) and DBA/1J (stock number: 670) were purchased from Jackson Laboratories
(Bar Harbor, Maine, USA) via UK agent Charles River (Margate, Kent, UK).
Mouse embryonic stem cells
Irradiated mouse embryonic fibroblasts (MEFs) as a feeder layer and mESCs of C57BL/6
mouse strain were purchased from Life Technologies (Paisley, U.K.). MEFs were cultured in
high glucose D-MEM media supplemented with 10% fetal bovine serum (FBS; embryonic
4stem cell certified). Cells were seeded in the cell culture flasks coated with 0.1% attachment
factor (AF) at a density 25,000 cells/cm2 and cultured at 37°C in 5% CO2 and 95% air-water
saturated atmosphere. After 2 - 4 days, mESCs were seeded over the feeder layer at density
50,000 cells/cm2 and incubated under the same atmosphere. The media used for mESCs was
Knockout™ D-MEM supplemented with 15% knockout serum replacement, 1% MEM non-
essential amino acids solution, 1% L-glutamine, 0.001% leukaemia inhibitory factor and
0.00182% 2-mercaptoethanol. For the experiments performed under hypoxic condition, cells
were incubated in hypoxia chamber gassed with 3% oxygen, 5% carbon dioxide and 92%
nitrogen at 37°C. The mESC media and hypoxic atmosphere were changed daily and mESCs
were passaged every 2 - 3 days when 80-90% confluent. To impose dicarbonyl stress on
mESCs, we added exogenous high purity MG. High purity MG was prepared and purified as
described [23]. To avoid phenotypic drift or differentiation of ESCs in culture, batches of
new mESCs were revived from cryostorage every 3 months and used for experiments at ≤ 
passage 15. mESC viability was assessed as the percentage of cells that exclude Trypan blue
and was determined after 3, 6 and 12 days of culture under 3% and 20 % oxygen atmosphere
conditions.
When the mESCs were ready for passage, medium was removed and flasks washed
with phosphate-buffered saline (PBS). Approximately 1 ml/25 cm2 StemPro Accutase
solution (Life Technologies) was added to each flask and cells returned to 37°C incubator for
3 - 5 min. StemPro Accutase solution was neutralised with supplemented D-MEM media.
Cell pellets were diluted to required concentrations depending on cell density and added to
new sterile polystyrene culture vessels coated with 0.1% AF and without a feeder layer.
Human blood samples
Whole blood samples were collected from healthy human subjects and patients with renal
failure (stage 5 chronic kidney disease). Samples were collected with written informed
consent using ethylenediaminetetra-acetic acid (EDTA) as anticoagulant. Clinical
characteristics of the participants are given (Supplementary Table S1). Healthy human
subjects and patients were recruited at the University Hospitals Coventry & Warwickshire
NHS Trust, Coventry, U.K. The study was approved by National Research Ethics Service
Committee West Midlands - Coventry & Warwickshire; project number 05/Q2802/26.
Samples were stored at -80ºC until analysis. The experiments conformed to the principles set
out in the WMA Declaration of Helsinki and the Department of Health and Human Services
Belmont Report.
DNA Extraction
DNA extraction was performed using the DNeasy Blood & Tissue kit according to the
manufacturer’s instructions (Qiagen, Manchester, UK). Samples were: 1 x 106 cells, 10 - 25
mg tissue or 200 μl whole human blood. The quality and concentration of DNA was 
determined spectrophotometrically using a NanoDrop 1000 spectrophotometer.
PCR analysis for Glo1 mutant mouse genotype
Primers used are given in Supplementary Table S2. The reaction mixture contained: 1 mM
dNTPs, 1.5 mM Mg2+, 0.2 pmol/µl forward and reverse primers, 2 µl 100 ng/μl DNA, Taq 
polymerase, stabilizer and buffer to the final volume of 20 µl. The protocol used for PCR
was: initial denaturation 4.5 min at 94°C, 30 cycles of denaturation (0.5 min at 94°C)-
annealing (0.5 min at 58°C)-elongation (0.5 min at 72°C), and final elongation (7.0 min at
72°C). PCR product (5 µl) was electrophoresed (100 V, 90 min) on 2% agarose gels stained
with 0.5 μg/ml ethidium bromide. The bp marker used was Hyperladder V (Bioline, London, 
5U.K.). Gels were photographed using ultraviolet light by ChemiGenius2 (Syngene,
Cambridge, U.K.).
Gene copy number and gene expression analysis - TaqMan® method
Glo1 copy number assays were performed by the TaqMan® Copy Number Assays, with
reference genes Tfrc and TERT for mouse and human DNA samples, respectively (Applied
Biosystems, Paisley, Scotland). They were performed using the manufacturers protocol (PN
4397425) and data analysed by CopyCaller™ software. mRNA expression analysis was
performed using the Taqman gene expression assay protocol (PN 4333458) according to the
manufacturer’s instructions. Rn 18s was internal reference gene with primers QT01036875
(Qiagen).
Glo1 copy number analysis - Paralogue ratio test
Accuracy of qPCR in application for copy number change analysis has been challenged and
an alternative procedure developed and applied called the paralogue ratio test (PRT) [24]. A
disadvantage of the PRT is greater sensitivity to template degradation than qPCR [25]. PRT
primers (Supplementary Table S2) were designed, using online software PRTPrimer
(www.prtprimer.org) as described [24], to amplify a sequence unique to the Glo1 and exactly
one other unlinked reference locus in a single PCR reaction with the same pair of primers.
The reference primers used amplified the region of Glo1 on chromosome 17 of
chr17:30603393-30603637 which produced a PCR product of 244 bp. The primers also apply
the reference locus on chromosome 3 at chr3:58404865-58405084 which produced a product
of 219 bp. The PCR reaction mixture (20 µl) contained: 2 x Biomix red (10 µl; Bioline), 270
ng mouse genomic DNA, 0.375 µM forward and reverse primers and 3.75 mM MgCl2. The
protocol used for PCR was: initial denaturation 4.5 min at 94°C, 30 cycles of denaturation
(0.5 min at 94°C)-annealing (0.5 min at 60°C)-elongation (0.5 min at 72°C), and final
elongation (7.0 min at 72°C). The PCR products were then separated and quantified by
capillary electrophoresis on Applied Biosystems capillary sequencer (ABI 3730) using
fluorescently tagged PCR fragments and GeneScan™ LIZ® 500 Size Standard (Thermo
Scientific, Lutterworth, U.K.). Total run time was 45 min and denature time was 3 min at 95
oC. Data were analysed by Peak Scanner™ Software 2 (Applied Biosystems, Foster City,
USA). Ratios of Glo1/reference locus PCR product intensities were calibrated by PRT assay
of DNA from C57BL/6J and DBA/1J mice (Glo1 copy no = 2.0 and 4.0, respectively) –
extracted from liver samples from reference strain sources.
Comparative genomic hybridization (CGH) oligonucleotide array
CGH array analysis was performed using SurePrint G3 mouse CGH Microarrays 1x1M
according to the manufacturer’s instructions (protocol no G4410-90010: version 7.2; Agilent
Technologies LDA UK Limited, Stockport, Cheshire). Reference samples were from
C57BL/6 mouse strain, gender-matched to sample DNA. Briefly, genomic DNA samples
(0.5 μg in 20.2 μl acetate-EDTA buffer) were digested by Alu I/Rsa I restriction enzyme 
mixture using SureTaq complete DNA labelling kit, according to the manufacturer’s
instructions (Agilent). The master mix was added to each reaction tube containing genomic
DNA to a total volume of 26 μl. Samples were loaded in a thermocycler and incubated for 2 h 
at 37ºC, 20 min at 65ºC and then at kept 4ºC. The digested DNA (2 μl) was loaded on to 
0.8% agarose gels to analyse digestion fragments (200 and 500 bp). Labelled DNA was
mixed with Tris-EDTA buffer (430 μl; pH 8.0) and purified with the mini-column provided 
in the SureTaq DNA labelling kit, repeating the wash step and collecting the DNA (total
volume: 80.5 μl). An aliquot (1.5 μl) was used for determination of yield, degree of labelling 
and specific activity by Nanodrop spectrophotometry. The remaining sample and reference
6DNA were mixed (158 μl), hybridisation master mix added, and heated to 95ºC for 3 min and 
then 37ºC for 30 min. The mixture was hybridized to the 1 M array using the Oligo
aCGH/ChIP-on-chip hybridization kit: loading 490 μl to the slide gasket and covering with 
the active side of the microarray. The sandwich slides were loaded into an Agilent microarray
hybridization chamber. This was placed in the hybridization oven heated to 60ºC and rotated
at 20 rpm for 40 h. Following hybridization, the array was washed with Oligo aCGH/ChIP-
on-chip wash buffer 1 and 2 and scanned using a Surescan microarray slide holder and
Surescan microarray scanner. All data was processed and collected by Feature Extraction
software and data analysed with Genomic Workbench Edition 7.0 (Agilent).
PCR–restriction fragment length polymorphism for Glo1 genotyping
C419A polymorphism in exon-4 of Glo1 was determined by PCR–restriction fragment length
polymorphism. PCR mixtures contained: 200 ng human genomic DNA, Biomix red (10 μl) 
and C419A genotyping forward primer and reverse primer. Each reaction contained 1 mM
dNTPs, 1.5 mM MgCl2, 0.2 pmol/µl forward and reverse primers, Taq polymerase, stabilizer
and buffer to the final volume of 20 µl. The PCR products were digested with SfaNI
restriction enzyme (New England Biolabs Ltd, Hitchen, UK) for 1 h at 37ºC. The digested
product were resolved by 2% agarose gel electrophoresis and the fragments were visualized
under UV light after staining with ethidium bromide to identify the single base pair change.
The restriction digest reveals 453 bp and 260 bp fragments for the C419 allele (rs4746 C332)
and 713 bp fragment for the A419 (rs4746 A332) allele [26].
Characterisation of the glyoxalase system and methylglyoxal metabolism
Activities of Glo1 and Glo2 were assayed spectrophotometrically, Glo1 protein and Glo1
mRNA were assayed by Western blotting and RT-PCR, and MG, glycation adduct MG-H1
and creatinine were assayed by stable isotopic dilution analysis liquid chromatography-
tandem mass spectrometry (LC-MS/MS), as described [23, 27-30]. MG reductase activity
was determined spectrophotometrically as described [31] with minor modification: using 1
mM MG as substrate and 50 mM sodium phosphate buffer, pH 7.4 at 37°C, as the assay
buffer. D-Lactate was measured by endpoint enzymatic assay with microplate fluorimetry
[32]. Total protein was assayed by the Bradford method.
Statistical analysis
Data of copy number change, mRNA and other variables of mouse samples were analysed for
normality (Kolmogorov Smirnov test), confirmed as approximating to normal distribution
and sample group means analysed for significance of difference by independent sample
Student’s t-test. Similar data of mESC analysis was assumed to be normally distributed and
the t-test applied. Clinical copy number data was similarly analysed for normality, confirmed
and analysed by one sample t-test (99% CI) to identify renal failure patients with abnormally
low or high Glo1 copy number. Urinary MG-H1 data were non-parametrically distributed and
sample groups were analysed for significance of difference by Mann-Whitney U test. DNA
microarray data were analysed by the ADM-2 algorithm with threshold P<1 x 10-6, with ≥3 
consecutive probes and log2 R ratio of ≥ 0.25. Factors linked to increased GLO1 copy 
number in the clinical study were explored by partial least squares-discriminant analysis
(PLS-DA) using XLSTAT software (Addinsoft, New York, USA). For healthy control
subjects and patients with chronic kidney disease combined, GLO1 gene copy number
association was analysed with the following variables: age, gender, body mass index (BMI),
ethanol consumption, smoking status, systolic and diastolic blood pressure, haemoglobin,
plasma glucose, glycated haemoglobin HbA1c and serum creatinine – Table S1. A similar
PLS-DA was performed on glyoxalase-related variables (Glo1 activity, Glo1 protein, Glo1
7mRNA, liver MG and urinary MG-H1) in wild-type and Glo1 (+/-) mutant mice combined to
assess associations with presence of the Glo1 mutant allele – Table 1. An association was
judged present when the 95% confidence interval of the variable coefficient excluded zero.
RESULTS
IMKC Mutant mice have normal Glo1 expression with two wild-type copies and one or
more mutated copies of Glo1
We initially assessed the genotype of the Lexicon Glo1 mutant mice by qPCR using 3 pairs
of primers: one to detect wild-type Glo1 and two others to detect each end of the inserted
DNA in mutated Glo1 (with primer sequence design for inserted DNA made in collaboration
with Lexicon Pharmaceuticals) – Supplementary Table S2. Forty-four wild-type and Glo1
mutant mice were genotyped. The product size with each primer was 237 bp, 139 bp and 242
bp respectively (Figure 1d and 1e). The genotype distribution of the mice was 9 wild-type
and 35 heterozygote. No homozygotes were detected. We analysed activity of Glo1 in tissues
(liver, kidney, brain, heart, skeletal muscle, brain and pancreas) of wild-type and Glo1 mutant
mice at 3 and 7 months of age and found no significant difference in any tissue at either time
point (Table 1). We analysed Glo1 expression by immunoblotting of Glo1 protein
(Supplementary Figure S1) and by RT-PCR of Glo1 mRNA. We found no significant
difference between wild-type controls and Glo1 mutant mice (Table 1). We also analysed
other components of the glyoxalase system – activity of Glo2, concentrations of MG and D-
lactate, and tissue protein content of MG-derived glycation adduct MG-H1 and found no
significant change in Glo1 mutant mice, with respect to wild-type controls (Table 1). There
was also no change in whole body formation of MG-H1 glycation adducts, as judged by flux
of urinary excretion of MG-H1 free adducts (median [lower – upper quartile]; nmol per mg
creatinine): wild-type controls - 47.0 [24.7 – 66.7], n = 10, and Glo1(+/-) mutant - 31.9 [13.0
– 39.1], n = 10; P>0.05, Mann-Whitney U. Where Glo1 is functionally inactivated, an
alternative fate of MG metabolism is by aldoketo reductases [33]. There was also no change
in activity of MG reductase; MG reductase also had very low activity in the liver of both
wild-type control and Glo1(+/-) mutant mice (Table 1). Therefore, Glo1 mutant mice have a
mutated Glo1 gene but with compensatory Glo1 expression and MG metabolism identical to
that of wild-type controls. Glo1 expression and levels of MG in Glo1 Lexicon mutant mice
found herein are typical of wild-type controls. This explains the unexpected normal, healthy
phenotype of Glo1 mutant mice reported in the IMKC project.
To explore the mechanism of compensatory Glo1 expression we quantified Glo1 copy
number by TaqMan® method, normalizing response to transferrin receptor protein-1 Tfrc
known to be present in two copies and located on chromosome 16 - different to that of Glo1.
For quantification of Glo1 DNA, we chose primers targeted to the 3’-end of exon 1 and the
5’-end of exon 6 in the Glo1 gene. DNA was extracted from the liver, kidney, brain and
pancreas. DNA from wild-type siblings was used as control with two copies of Glo1 and also
DNA from DBA/1J mice known to have gene duplication and 4 copies of the Glo1 gene.
Glo1(+/-) mutant mice had 3 copies of Glo1 in all tissues analysed with amplification
extending from 3’-end of exon 1 to the 5’-end of exon 6 (Table 2). Compensatory expression
of Glo1 occurred, therefore, from an additional wild-type copy of Glo1. We designed a
further Taqman copy number assay with primers and probe that detected DNA across the
insertion point of Glo1 and VICTR48 to quantify also the number of mutant
Glo1Gt(OSTGST_4497-D9)Lex alleles (abbreviated to Glo1Gt(..)Lex). Combination of these Taqman
copy number assays enabled assessment of the number of wild-type Glo1 and mutant
Glo1Gt(..)Lex copies. Most mutant mice contained two copies of wild-type Glo1 and one copy
of mutant Glo1Gt(..)Lex - designated Glo1(+/+)Gt(..)1Lex. In some cases, however, we found 2
8copies of both Glo1 and Glo1Gt(..)Lex – designated Glo1(+/+)Gt(..)2Lex. We investigated
inheritance patterns of the Glo1Gt(..)Lex alleles in litters from mating of different genotypes.
The offspring genotype pattern suggested a simple Mendelian inheritance (Table 3). From
mating of wild-type and Glo1(+/+)Gt(..)2Lex mice, offspring of only Glo1(+/+)Gt(..)1Lex mice
indicated the presence of a Glo1Gt(..)Lex mutant allele on each homologue of chromosome 17
(Table 3). From the principles of Mendelian inheritance, mating of wild-type mouse and
Glo1(+/+)Gt(..)2Lex mutant mouse producing a litter with all offspring having a single mutant
Glo1 allele, Glo1(+/+)Gt(..)1Lex, indicates that each offspring has received a mutant Glo1 allele
and wild-type Glo1 allele from the Glo1(+/+)Gt(..)2Lex mutant mouse parent originating from
either of the chromosome homologues inherited. Hence, Glo1(+/+)Gt(..)2Lex mice have a
mutant Glo1 allele and a wild-type Glo1 allele on each chromosome homologue.
Accordingly, it was not possible to produce progeny with < 2 copies of wild-type Glo1 alleles
and deficient in Glo1 expression and activity since each homologue of chromosome 17
retained a Glo1 wild-type allele. This was indeed observed throughout all breeding of Glo1
mutant mice.
PLS-DA analysis showed no significant association of Glo1-linked variables with
presence of the mutant allele, Glo1(+/+)Gt(..)1Lex, supporting the presence of wild-type
glyoxalase-related expression and metabolism in Lexicon Glo1 mutant mice.
Paralogue ratio test for Glo1 copy number
We measured copy number in this study by qPCR and later DNA microarray – see above.
Accuracy of qPCR in application for copy number change analysis has been challenged and
an alternative procedure developed and applied called the paralogue ratio test (PRT). We
developed a PRT for murine Glo1. Application of this gave similar corroborative estimates of
Glo1 copy number by PRT were: genotype Glo1(+/+), 2.00 ± 0.11; Glo1(+/+)Gt(..)1Lex, 2.84 ±
0.20 (P<0.01 with respect to Glo1(+/+)); Glo1(+/+)Gt(..)2Lex, 4.18 ± 0.09 (P<0.001 with
respect to Glo1(+/+) and Glo1(+/+)Gt(..)1Lex). Estimates of Glo1 copy number by qPCR and
PRT also corroborated well with DNA microarray analysis – see below.
Copy number increase is focussed to and selective for the Glo1 genomic domain
Finding that Lexicon mutant mice had increased Glo1 copy number, we sought to identify the
location of copy number increase in genomic DNA. We performed high intensity genome-
wide DNA microarray analysis, analysing 3 mice of each genotype: Glo1 (+/+),
Glo1(+/+)Gt(..)1Lex and Glo1(+/+)Gt(..)2Lex. In wild-type controls, there was no cop number
increase detected at the Glo1 locus, confirming that wild-type mice had two copies of Glo1.
In Glo1(+/+)Gt(..)1Lex mice, a segment of 473,479 bp DNA hybridising with 300
oligonucleotides had mainly one additional copy; mean copy number 2.76. In
Glo1(+/+)Gt(..)2Lex this fragment had mainly 2 additional copies; mean copy number 3.61
(Figure 2). The copy number change region comprised Glo1 and Dnahc8 (dynein, axonemal,
heavy chain 8) and part of Btbd9 (BTB (POZ) Domain Containing 9) and Glp1r (glucagon-
like peptide 1 receptor) genes. Other regions of the mouse genome showed random
duplication in different areas occurring in only one donor and not linked to the Glo1 mutant
genotype. Only two genes in a different common domain were duplicated in Glo1 mutant
mice: Vmn2r111 and Vmn2r112 (vomeronasal 2, receptors 111 and 112), on chromosome 17
(22673192 to 22797105) and detected by 20 oligonucleotides in the Glo1(+/+)Gt(..)1Lex and 20
oligonucleotides in Glo1(+/+)Gt(..)2Lex mice with mean copy numbers of 2.70 and 3.27,
respectively. Copy number change of Btbd9, Dnahc8 and Vmn2r112 did not produce
concomitant increased expression, as judged by change in relative mRNA level; Vmn2r111
was not investigated. Indeed, expression of Vmn2r112 was decreased moderately in
Glo1(+/+)Gt(..)1Lex mice and markedly in Glo1(+/+)Gt(..)2Lex mice (Supplementary Figure S2).
9Copy number increase of Glo1 in mouse embryonic stem cells induced by dicarbonyl
stress in vitro
We hypothesised that dicarbonyl stress in mESCs may increase Glo1 copy number by
induced copy number alteration as an adaptive genomic cytoprotective response. To explore
this we studied the effect of exposure of mESCs to exogenous MG in vitro. Survey of
expression of mESC markers, SOX2, Nanog and Oct4, confirmed maintenance of the mESC
phenotype throughout. mESC growth and viability and the glyoxalase system were studied
under atmospheres containing 20% and 3% oxygen - typical of most cell culture conditions
and mESC oxygen exposure in vivo, respectively. mESC growth and expression and activity
of Glo1 was decreased in 3% oxygen growth conditions (Figure 3a – 3d). Consumption of
glucose and net formation of L-lactate was increased in 3% oxygen cultures, reflecting
increased anaerobic glycolysis (Figure 3e and 3f). Concomitant increased flux of formation
of D-lactate was found – a measure of flux of formation of MG in anaerobic glycolysis and
metabolism of MG by the glyoxalase system (Figure 3g).
To impose dicarbonyl stress on mESCs, we added exogenous high purity MG.
Incubation of mESCs with MG for 2 days under 20% oxygen growth conditions produced
decreased growth and viability with a median growth inhibitory concentration GC50 = 848 ±
42 μM (N = 15) - Figure 4a. In addition, cell viability of mESCs decreased with > 50 μM MG 
under 20% oxygen growth conditions – Figure 4b, suggesting the inhibition of cell growth by
MG is due to both growth arrest and toxicity. This was potentiated under 3% oxygen growth
conditions (Figure 4a and 4b). We incubated mESCs for 12 days with 200 μM MG, changing 
the medium and added fresh MG every 24 h. At 3, 6 and 12 days, the copy number of Glo1
was increased to a maximum of +16%. Copy number of other genes duplicated with Glo1 in
mutant mice, Btbd9 and Dnahc8, was examined and no change was found (Table 4). The
increase in Glo1 copy number at day 12 with MG treatment was associated with an increase
in Glo1 protein: Glo1 protein (normalised to β-actin) – control, 0.49 ± 0.01 versus 0.62 ± 
0.04, + 27%; P<0.01 (n = 3) (Figure 4c). Similar increase in Glo1 copy number occurred in
mESCs incubated under 3% oxygen but it was not increased further with addition of
exogenous MG (Figure 3h). Percentage viability of mESCs at 3, 6 and 12 days incubated
under 20% oxygen was: control – 98 ± 1, 97 ± 1 and 96 ± 1, and + 200 μM MG - 96 ± 2, 97 ± 
1 and 96 ± 1 (n = 3). Similar percentage viability of mESCs at 3, 6 and 12 days incubated
under 20% oxygen was: control – 96 ± 8, 97 ± 3 and 97 ± 2, and + 200 μM MG - 94 ± 16, 64 
± 9 and 94 ± 10 (n = 3). Daily exposure to 200 μM MG continually slowed cell growth and 
thereby likely decreased toxicity to MG.
Glo1 copy number increase in clinical dicarbonyl stress
The relevance of Glo1 copy number increase to human health and disease was assessed in
clinical translation by study of a disease associated with severe dicarbonyl stress - renal
failure (stage 5 chronic kidney disease) [34]. We also characterised genotype of subjects with
respect to the common single nucleotide polymorphism (SNP) C419A (Supplementary
Figure S3). We examined DNA of peripheral blood mononuclear cells of healthy subjects and
patients with renal failure. Subject and patient characteristics are summarised (Supplementary
Table S1). In healthy subjects, GLO1 copy number was (mean ± SD): 2.00 ± 0.13 (n = 21). In
20 renal failure patients, we found 15 patients had GLO1 copy number indistinguishable from
healthy controls, one had an abnormally low GLO1 copy number (1.69, P<0.001) and 5 renal
failure patients had GLO1 copy number higher than healthy controls for which GLO1 copy
number (mean ± SD) was 2.18 ± 0.03 (n = 5, P<0.001). In renal failure patients, therefore,
the prevalence of Glo1 copy number increase was 25% with a mean GLO1 DNA increment
of 9%. This copy number increase is of relatively high prevalence but low in magnitude
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compared to GLO1 duplication in the healthy population. For the SNP C419A, in renal
failure patients the genotype distribution (CC, CA, AA) was: no GLO1 copy number increase
- 3:7:4, presence of GLO1 copy number increase – 0, 2, 3. The SNP for one patient could not
be discerned. The change in genotype distribution was not significantly different (Fisher
Exact test). There was no distinctive renal failure etiological or clinical chemistry
characteristics of patients with GLO1 copy number increase.
PLS-DA analysis showed a significant association of increased GLO1 copy number
with increased serum creatinine and decreased alcohol consumption. Standardised
coefficients were: serum creatinine 0.363 ± 0.155, and alcohol consumption – 0.173 ± 0.082.
Model cumulative Q2 = 0.155.
DISCUSSION
Herein we show that mutation to Glo1 by gene trapping in the IMKC project failed to produce
a Glo1 deficient mouse because of the presence of an additional copy of the wild-type Glo1
gene. The genetic domain duplicated is similar to that found endogenously in some strains of
mice [35]. Glo1 duplication is not present in the genetic background of C57BL/6J mice – the
strain used in production of the Lexicon Glo1 mutant mice [35]; nor was it present in the
129SvEvBrd ESC line when assessed in 2005 [36]. However, the genome sequence of the
129SvEvBrd ESC cell line assessed later in the Mouse Genomes Project (Sanger Institute)
shows Glo1 duplication [37]. The disparity between this and the earlier contradictory report
may be due to instability of copy number increases in ESC lines. In a study of copy number
variation (CNV) stability in ESC lines, about 50% of CNVs studied in multiple clonal lines
were not found in their common parental ESC line, indicating that CNVs may change
through CNV instability during mitosis with prolonged sub-culturing [38]. The origin of the
additional Glo1 gene copy in Lexicon mutant mouse is likely due to Glo1 duplication in the
29SvEvBrd ESC clone used before gene trapping. Glo1 deficiency was thereby prevented in
all siblings and progeny of the Lexicon Glo1 mutant mouse. The current description of this
mouse line in the EMMA as Glo1 deficient mouse is, therefore, incorrect and requires
amendment.
DNA microarray analysis of Lexicon Glo1 mutant mice revealed focussed and
selective functional Glo1 duplication with secondary effects on genes susceptible to copy
number change, Vmn2r111 and Vmn2r112. There is no known link of the glyoxalase system
to the pheromone signalling in mammals. Pheromone receptor genes are highly enriched in
copy number changes, being present in large gene families characterized by rapid evolution
with many pseudogenes and highly variable gene content between species [39]. This may
account for the copy number change of Vmn2r111 and Vmn2r112 herein. Engineered copy
number change or mutation of single genes has previously been found to induce copy number
change of unrelated genes and mutations in secondary effect genes leading to impaired
expression [40]. For Vmn2r112 there was moderate and markedly decrease in expression in
Glo1(+/+)Gt(..)1Lex and Glo1(+/+)Gt(..)2Lex mutant mice, respectively. This decrease in
expression indicates that copies of Vmn2r112 are weakly or mostly non-functional and in
Glo1 mutant mice which is likely linked to Vmn2r112 gene disruption.
To explore the possibility that Glo1 may suffer dicarbonyl stress-induced copy
number alteration, we studied prolonged exposure of mESCs in vitro to severe dicarbonyl
stress imposed by high concentrations of exogenous MG [1]. For physiological relevance we
studied Glo1 activity and copy number changes also under an atmosphere of 3% oxygen –
equivalent to ambient oxygen concentration for embryonic stem cells in vivo [41]. We found
low level increased copy number focussed to the Glo1 genomic domain induced to a similar
level by addition of exogenous MG, 3% oxygen, and exogenous MG and 3% oxygen
together. A possible driver for this is aneuploidy which occurs spontaneously in ESCs in long
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term culture. This is an unlikely explanation for Glo1 copy number increase, however, as: (i)
Glo1 is not a genetic locus found increased in ESCs in genome-wide studies when cultured
under 20% oxygen atmosphere [42]; (ii) genes proximate to the Glo1 genetic locus, Btbd9
and Dnahc8, were not increased in copy number along with Glo1 – indicating that the
increase in copy number was specific for the Glo1 locus and not the whole or substantial
fragment of the chromosome; and (iii) Glo1 copy number was increased in mESCs in vitro
under an atmosphere of 3% oxygen, or hypoxia, which are conditions where genomic
instability and aneuploidy in ESCs is decreased [43, 44]. Rather, it appears that increase in
Glo1 copy number in response to dicarbonyl stress and hypoxia is a programmed and not a
spontaneous characteristic of mESCs in vitro.
Interestingly there are precedents of hypoxia-induced gene copy number increase:
Black et al. reported genetic domain specific increase of gene copy number to levels similar
to those of Glo1 herein in primary human T-lymphocytes and tumours – including genes
linked to multidrug resistance (MDR) [45]. This was driven by histone demethylase KDM4A
[46]. Glo1 is implicated in cancer MDR [47]. It is likely that Glo1 copy number increase
herein was driven by a similar mechanism. Blank et al. did not investigate copy number
change at the Glo1. Glo1 had increased expression in hypoxia-adapted tumour cell lines but
copy number was not investigated as a possible mediating factor [48].
For the hypoxia response, we found decreased Glo1 activity in mESCs under 3%
oxygen (Figure 3b). This occurred despite a concurrent small increase in Glo1 copy number
(Figure 3h). This was expected because down-regulation of Glo1 expression in hypoxia is
driven by hypoxia-inducible factor 1-alpha (HIF1α) and typically decrease Glo1 expression 
by ca. 30% [49], greater than the increase in Glo1 copy number in short-term culture,
producing an overall decrease in Glo1 expression and activity (Figure 3b – 3d). It is likely
that hypoxia-induced Glo1 copy number is increased by KDM4A or similar mechanisms –
see above. This remains to be determined in future studies. We propose that high
concentrations of MG either activate KDM4A or by direct glycation achieve similar
functional change in histone proteins to KDM4A-driven demethylation. This would explain
why hypoxia and MG treatment achieve the same level of induced Glo1 copy number
increase individually and together. We propose that hypoxia-activated processes in ESCs
under 3% oxygen environment in vivo may contribute to low GLO1 duplication in mouse and
human populations [35, 50, 51].
Glo1 may be a focus of copy number increase due to the protection afforded by
increased Glo1 protein and activity against dicarbonyl stress-induced cytotoxicity. Severe
dicarbonyl stress also induces decreased cell growth and viability – as we and others have
found previously in ESCs, other cell types, mouse oocytes, fertilization, and fetal
development [52-54]. Mild dicarbonyl stress was induced by mESC culture in 3% oxygen -
through down regulation of Glo1 expression and increased anaerobic glycolysis with increased
flux of formation of MG. The latter was indicated by increased flux of formation of D-lactate,
formed from metabolism of MG by the glyoxalase system [3]. We found increased
consumption of glucose and net formation of L-lactate in 3% oxygen cultures reflecting
increased anaerobic glycolysis, as found previously [55].
Cytoprotective responses in cells are usually achieved through signalling pathways
activating change in gene expression through regulation of transcription and translation [56,
57]. A higher regulatory level of generational duration producing increased expression of
cytoprotective genes may be achieved by inducible functional gene copy number increase or
copy number alteration [58]. Inducible copy number increase of Glo1 in dicarbonyl stress
provides an example of adaptive genomics for cytoprotective response. A precedent for this is
oxidative damage-induced gene duplication arising from chromosomal instability in
Saccharomyces cerevisiae [59]. This was not focused for genes associated with alleviation of
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oxidative stress. Also, there is the precedent of chronic exposure of HA1 Chinese hamster
fibroblasts in vitro to supraphysiological concentrations of oxygen or hydrogen peroxide
(95% oxygen or 800 μM hydrogen peroxide for >200 days) which increased copy number of 
cytoprotective catalase (CAT) [60]. Genome-wide copy number change was not investigated
and hence it is uncertain if the copy number increase was focussed to and selective for CAT.
Dicarbonyl stress increases modification of both protein and DNA by MG [4, 5]. MG
modification is a major cause of endogenous DNA damage: MGdG is the major quantitative
adduct of endogenous DNA damage in vivo and is associated with mutagenesis [5]. Increased
functional Glo1 copy number provides for cytoprotective response and survival against
dicarbonyl stress. This survival advantage may account for why GLO1 copy number increase
is retained in some instances. Large transcription units drive locus-specific genomic
instability during DNA replication. They are replicated late in the cell cycle and organize
copy number duplications in their flanking regions. This is thought to occur through
transcription-dependent double-fork failure in DNA replication [61]. The Glo1 gene is
present in a large transcriptional domain of the genome at the flanking region of Btbd9 in
which copy number increases are enriched.
Increased gene copy number found and retained in the mammalian genome are
considered to be limited to genes where copy number increase confers cell growth or survival
advantage [62]. Cahan et al. found Glo1 copy number increase in mice produced increased
Glo1 expression in all tissue and cell types tested - hypothalamus of brain, adipose tissue and
hematopoietic stem cells, with similar copy number increase at all sites [50]. A genome-wide
scan of copy number variation in the human population, however, did not reveal a
predominance of cytoprotective genes [51]. Many copy number increases are found at low
prevalence (<5%) and may occur stochastically. Hence, unless survival pressures are
experienced population-wide and continually, copy number alteration for cytoprotective
responses may go undetected among a background of random copy number increases. No
example of copy number increase in response to exposure to high and toxic levels of
endogenous metabolites focussed to gene linked to cytoprotective response has hitherto been
presented.
In clinical translation we found evidence of Glo1 copy number increase in renal
failure. We studied renal failure as an example of severe dicarbonyl stress: plasma MG
concentration in healthy subjects is ca. 100 nM and increases 5 – 7 fold in renal failure [1,
63]. The prevalence of increased GLO1 copy number was higher than spontaneous GLO1
duplication in the human population of ca. 2% [51]. Chronic hypoxia is also a common
characteristic of renal failure [64]. We propose GLO1 copy number increase in renal failure
is due to dicarbonyl stress and/or hypoxia. Decreased GLO1 copy number in one renal failure
patient was likely due to DNA damage induced by uremic toxins [65]. There was no
association of increased GLO1 copy number with the common SNP C419A. This is expected
as the polymorphism gives rise to dimer allozymes with identical enzymatic activity [66, 67]
and therefore genotypes may be equally exposed to dicarbonyl stress and thereby similarly
susceptible to GLO1 copy number increase. Increased GLO1 copy number in peripheral
blood mononuclear cells of patients with renal failure may, therefore, reflect induced GLO1
copy number increase in hematopoietic stem cells and their progeny. The clinical significance
of increase in GLO1 copy number in renal failure remains to be determined and could be
linked to increased survival. The positive association of increased Glo1 copy number with
serum creatinine concentration in PLS-DA is consistent with renal failure as a driver for
GLO1 copy alteration. The negative association with alcohol consumption was surprising and
interesting but requires validation in further studies.
Studies of GLO1 copy number alteration in other health impairment and disease are
of interest – particularly cancer. We previously found increased GLO1 copy number in some
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drug naïve human tumours associated with increased Glo1 expression. Increased GLO1 copy
number was often functional giving rise to high Glo1 expression and activity permissive for
tumour growth in a background of high flux of MG formation [5, 68]. Increased Glo1
expression also confers MDR in cancer chemotherapy [69]. Copy number alteration of GLO1
in the early stages of tumour development by exposure to increased MG from high glycolytic
activity associated with tumour metabolic re-programming and hypoxia [70, 71] may,
through clonal selection, lead to dominant functional increased functional GLO1 copy
number and MDR. This is supported by observations in malignant melanoma, for example,
where GLO1 copy number increase has low prevalence (2%) in early stages and high
prevalence (80 - 89%) in advanced stages [68, 72, 73]. Recent studies have found very high
prevalence of GLO1 copy number increase also in gastric cancer (33%) [74] and in “triple
negative” breast cancer lacking expression of oestrogen and progesterone receptors and
epidermal growth factor receptor-2 genes (83%) [75]. These tumour types do not respond
well to currently available chemotherapy; such tumours may be sensitive to permeable Glo1
inhibitor chemotherapy when available clinically [47]. In gastric cancer increased GLO1
copy number was linked to Glo1 expression and was a negative survival factor [74]. GLO1
copy number alteration through dicarbonyl stress and/or hypoxia may contribute to the
development of Glo1-linked MDR in cancer chemotherapy. Other conditions of clinical
hypoxia may display low level GLO1 copy number increase in mitotic cells.
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Table 1 Activity and expression of Glo1 and related metabolites in Glo1 mutant mice and wild-type controls.
Analyte Study group Liver Kidney Brain Heart Pancreas Spleen
Glo1 activity
(U/mg protein)
Wild-type 4.36 ± 0.77 0.77 ± 0.14 1.89 ± 0.34 1.00 ± 0.16 0.60 ± 0.05 0.33 ± 0.08
Glo1(+/-) mutant 3.68 ± 0.70 0.78 ± 0.13 2.02 ± 0.43 0.96 ± 0.09 0.64 ± 0.05 0.45 ± 0.12
Glo1 protein
(normalised to β-actin) 
Wild-type 4.98 ± 1.46
Glo1(+/-) mutant 5.12 ± 1.93
Glo1 mRNA
(normalised to Rn 18s)
Wild-type 0.43 ± 0.02 0.55 ± 0.03
Glo1(+/-) mutant 0.41 ± 0.02 0.54 ± 0.04
Glo2 activity
(mU/mg protein)
Wild-type 0.11 ± 0.02
Glo1(+/-) mutant 0.11 ± 0.01
Methylglyoxal
(pmol/mg wet weight)
Wild-type 4.33 ± 0.65
Glo1(+/-) mutant 4.31 ± 1.02
D-Lactate
(nmol/mg wet weight)
Wild-type 0.34 ± 0.06
Glo1(+/-) mutant 0.34 ± 0.06
MG-H1
(mmol/mol arg)
Wild-type 0.45 (0.33 – 0.51)
Glo1(+/-) mutant 0.38 (0.32 – 0.42)
MG Reductase activity
(U/mg protein)
Wild-type 0.00278 ± 0.00089
Glo1(+/-) mutant 0.00284 ± 0.00091
Data are mean ± SD or median (lower – upper quartile); n = 8, wild-type, and n = 9, Glo1(+/-) mutant mice.
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Table 2 Copy number variation in Glo1 mutant mice and wild type controls.
Exon-1 Exon-6
Tissue Wild-type Glo1 (+/-) mutant Wild-type Glo1 (+/-) mutant
Liver 2.02 ± 0.27 3.17 ± 0.28*** 2.01 ± 0.20 3.19 ± 0.30***
Kidney 2.02 ± 0.32 2.98 ± 0.26*** 2.00 ± 0.10 3.24 ± 0.29***
Brain 2.00 ± 0.06 2.97 ± 0.17*** 2.00 ± 0.11 3.04 ± 0.18***
Pancreas 2.00 ± 0.11 2.95 ± 0.20*** 2.01 ± 0.13 3.01 ± 0.22***
Data are mean ± SD (n = 8 wild-type and n = 9 Glo1 mutant mice). Significance: ***,
p<0.001; Student’s t-test.
Table 3 Inheritance of the Glo1Gt(OSTGST_4497-D9)Lex mutant allele.
Mated couple Litter
size
Glo1(+/+) Glo1(+/+)Gt(..)1Lex Glo1(+/+)Gt(..)2Lex
♀: Glo1(+/+)
♂: Glo1(+/+)Gt(..)1Lex
4 2 2 0
♀: Glo1(+/+)Gt(..)1Lex
♂: Glo1(+/+)Gt(..)1Lex
6 2 3 1
♀: Glo1(+/+)
♂: Glo1(+/+)Gt(..)2Lex
7 0 5 0
Glo1 Copy number was determined by the Taqman method and allele typing by qPCR.
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Table 4 Effect of exogenous methylglyoxal on copy number of Glo1 and neighbouring genes in murine embryonic stem cells in
vitro.
Incubation period (days)
0 3 6 12
Gene Copy number Copy number
Change
(%) Copy number
Change
(%) Copy number
Change
(%)
Glo1(Exon1) 2.00 ± 0.10 2.11 ± 0.07** 5 2.15 ± 0.11** 7 2.32 ± 0.09*** 16
Glo1(Exon6)
2.00 ± 0.09
2.19 ± 0.09** 9
2.15 ± 0.11** 7 2.16 ± 0.05*** 8
Btbd9 2.00 ± 0.05 1.94 ± 0.20
Dnahc8 2.00 ± 0.05 2.04 ± 0.09
All analyses were performed in triplicate and copy number analyses were performed using Taqman Copy number assay. Data are mean ± SD (n
= 3). Significance: **: p<0.01, ***; p<0.001; Student’s t-test.
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FIGURE LEGENDS
Figure 1 Protein and nucleotide glycation and glyoxalase metabolism in dicarbonyl
stress and DNA Electrophoresis for PCR analysis of Glo1 mutant and wild-type control
mice. (a) Metabolism of methylglyoxal by the glyoxalase system. (b) Formation of
hydroimidazolone MG-H1 from arginine residues in protein. (c) Formation of
imidazopurinone isomers in DNA. The common 2’-deoxyribosyl group has been omitted for
clarity. (d) DNA Electrophoresis for PCR analysis of Glo1 mutant and wild-type control
mice. The figure shows an agarose gel stained with ethidium bromide. The first lane on the
left-hand side, Hyperladder V, shows electrophoresis of DNA bp size calibrators. Then lanes
are labelled by sample genotype: wild-type, Glo1(+/+)Gt(..)1Lex and Glo1(+/+)Gt(..)2Lex. (e)
Location of Primer target sequences in the Glo1 and Glo1 mutated gene. Solid bar, wild-type
DNA; hollow bar – inserted vector; arrows, primers. LTR = long terminal repeat. *, location
of VICTR48 insertion into Glo1 (+ 706 from the start codon).
Figure 2 Comparative genomic hybridization array of Glo1 mutant mice. An extract
of chromosome 17, 894 kb from 30379127 to 31273646. Genotype: (a) Glo1(+/+),(b)
Glo1(+/+)Gt(..)1Lex, and (c) Glo1(+/+)Gt(..)2Lex. Response key: log2R <0, green; log2R >0,
Reference DNA was from wild-type C57BL/6 mice. Data were analysed by Agilent
Genomic Work bench software. R is the ratio of the probe intensity to the average of
reference DNA (DNA combined from male and female wild-type mice). Normalised data
were analysed with algorithm ADM-2 with threshold of P<1 x 10-6 and minimum of 3
consecutive probes per region.
Figure 3 Glyoxalase pathway metabolism in mouse embryonic stem cells in vitro and
effect of low oxygen concentration. (a) Viable cell number per flask. (b) Glo1 activity.
(c) and (d) Glo1 protein – immunoblotting images and densitometric quantitation. (e)
Glucose consumption. (f) Net flux of L-lactate formation. (g) Flux of D-lactate
formation. mESCs were incubated for 6 days under the stated conditions. (h) Effect on
Glo1 copy number of incubation with and without 200 μM MG for 12 days under 
atmosphere of 20% or 3 % oxygen. Data are mean ± SD (n = 3). Significance: * and ***,
P<0.05 and P<0.001, respectively; Student’s t-test.
Figure 4 Inhibition of growth of mouse embryonic stem cells by methylglyoxal in
vitro – effect of oxygen concentration. (a) Effect on cell growth, viable cell number
count as a percentage of control. (b) Cell viability, percentage of cells remaining that
excluded Trypan blue. Key: □-□, cell incubations in 20% oxygen atmosphere; ■-■ cell
incubations in 3% oxygen atmosphere. mESCs were incubated as described in the
methods section with 0 – 200 μM MG for 48 h and Data are mean ± SD (n = 3). (c)
Western blot analysis of Glo1 protein in mESCs incubated with 200 μM MG. Control 
and test incubation blots are given in triplicate showing internal reference protein, β-
actin (42 kDa), and Glo1 (subunit molecular mass 23 kDa).
24
25
26
Supplementary information
Re-appraisal of putative glyoxalase 1 deficient mouse and dicarbonyl stress on
embryonic stem cells in vitro
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Supplementary Table S1 Characteristics of renal failure patients and healthy control subjects.
Variable Healthysubjects
Renal failure
patients
N 21 20
Gender (M/F) 11/10 10/10
Age (years) 54 ± 11 54 ± 9
Dialysis modality (pre-dialysis/peritoneal
dialysis/hemodialysis) ---- 6/2/12
Duration of dialysis (years) ---- 3.3 (1.3 – 7.8)
Serum creatinine (μM) 90 ± 17 622 ± 242***
BMI (kg/m2) 26.1 ± 3.3 26.2 ± 3.3
Ethnicity (Caucasian/Asian) 19/2 20/0
Alcohol consumption (Yes/No) 19/2 12/8
Smoking (Current/Ex/Never) 4/7/10 4/2/14
Systolic blood pressure (mmHg) 125 ± 14 139 ± 27*
Diastolic blood pressure (mmHg) 76 ± 9 77 ± 13
Hemoglobin (g/L) 135 ± 15 115 ± 15***
Fasting plasma glucose (mM) 5.5 ± 1.4 6.1 ± 1.5
HbA1c (mM) 40 ± 7 36 ± 5
GLO1 genotype rs4746 A/C332 (AA/AC/CC) 3/9/6 3/9/7
Data are mean ± SD or median (lower – upper quartile). Significance: * and ***, P<0.05 and
P<0.001 respectively; Student’s t-test. The causes of renal failure were: polycystic kidney
disease 4, Alport syndrome 2, interstitial nephritis 2, chronic pyelonephritis 2, reflux
nephropathy 2, hypertensive nephropathy 1, vasculitis 1, obstructive nephropathy 1, IgA
nephropathy, post-streptococal glomerulonephritis 1, undetermined 3. GLO1 genotype was
not determined in 3 subjects. Characteristics of patients with GLO1 copy number alteration:
dialysis modality – hemodialysis, 4, pre-dialysis, 1; cause of renal failure - polycystic kidney
disease 2, obstructive nephropathy 1, undetermined 2; GLO1 genotype rs4746 – AA, 3 and
AC, 2, CC, 0; and serum creatinine 746 ± 351 µM.
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Supplementary Table S2 PCR and PRT primers used in the study.
Study Primer no Sequence (Sense, Antisense)
Glo1 mutant mouse
genotype 1 (for wild-type Glo1)
Forward: 5'-TTGCTTGCTTGGCTTTGCCATTGC-3'
Reverse: 5'-GGACCACCACCTGAATGAGTCTTGC-3'
2 (for 5’- Glo1-
VICTR48 link)
Forward: 5'-TTGCTTGCTTGGCTTTGCCATTGC-3'
Reverse: 5’-TAAACCCTCTTGCAGTTGCATC-3’
3 (for VICTR48-3’-
Glo1 link)
Forward: 5’-AAATGGCGTTACTTAAGCTAGCTTGC-3’
Reverse: 5'-GGACCACCACCTGAATGAGTCTTGC-3'
C419A genotyping 5’-TCAGAGTGTGTGATTTCGTG-3’
5’-CATGGTGAGATGGTAAGTGT-3’
PRT (mouse) Forward: 5’-GGCACAGGTCTGTTTTGTGA-3’
Reverse: 5’-ATATTTCCAACTGGGTGGGAG-3’
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Supplementary figures
Figure S1 Glyoxalase 1 protein content of liver of wild-type and Glo1 mutant mice.
Specimen gels of immunoblotting for Glo1 protein with β-actin as house-keeping 
control. WT (n = 3) and Glo1(+/-) (n = 4) showing Glo1 protein (subunit molecular mass
23 kDa) and internal reference protein, β-actin (42 kDa).  
Figure S2 mRNA expression of the duplicated genes in liver tissue of wild-type mice,
Glo1(+/+)Gt(..1)Lex and Glo1(+/+)Gt(..)2Lex mice. Relative mRNA content: (a) Btbd9, (b)
Dnahc8, and (c) VMN2r112. Data are mean ± SD (n = 3). Significance: * and ***, P<0.05
and P<0.001 with respect to wild-type; and o and ooo, P<0.05 and P<0.001 with respect
to Glo1(+/+)Gt(..)1Lex; Student’s t-test.
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Figure S3 Specimen genotyping for C419A SNP in GLO1 gene. DNA ladder (bp
calibration standards) (Lane L). Two bands of 260 and 453 bp fragments indicative of
homozygous C419 allele (rs4746 C332) (Lane 1). Three bands of 713, 453 and 260 bp
indicative of heterozygous C/A419 alleles (Lane 2). A single band of 713 bp fragment
indicative of homozygous A419 allele (rs4746 A332) (Lane 3). The gel image shown is
cropped; all lanes were run in a single gel under the same conditions.
